Lineage Cell Therapeutics (LCTX) Interest & Investment Income (2013 - 2021)
Lineage Cell Therapeutics (LCTX) posted quarterly Interest & Investment Income of $2000.0 for Q1 2021, down 99.51% year-over-year from $405000.0 in Q1 2020, and little changed quarter-over-quarter from $2000.0 in Q4 2020.
Lineage Cell Therapeutics (LCTX) Interest & Investment Income (2013 - 2021) Analysis & Trends
Lineage Cell Therapeutics' Interest & Investment Income history runs 5 years deep, the most recent figure standing at $2000.0 for Q1 2021.
- In Q1 2021, Interest & Investment Income fell 99.51% year-over-year to $2000.0; the TTM figure through Mar 2021 stood at $636000.0 (down 61.41% YoY), while the FY2020 annual figure was $1.0 million, down 38.34% from the prior year.
- Interest & Investment Income for Q1 2021 stood at $2000.0, roughly flat from $2000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $442000.0 in Q1 2019, with the low at $2000.0 in Q4 2020.
- The 3-year median for Interest & Investment Income is $399000.0 (2019), against an average of $302888.9.
- Peak annual rise in Interest & Investment Income reached 8.37% in 2020, while the deepest fall reached 99.51% in 2020.
- Lineage Cell Therapeutics' Interest & Investment Income stood at $407000.0 in 2019, then sank by 99.51% to $2000.0 in 2020, then changed by 0.0% to $2000.0 in 2021.
- Business Quant data shows LCTX's Interest & Investment Income at $2000.0 in Q1 2021, $2000.0 in Q4 2020, and $252000.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 2,000.00 |
| Dec 31, 2020 | 2,000.00 |
| Sep 30, 2020 | 252,000.00 |
| Jun 30, 2020 | 380,000.00 |
| Mar 31, 2020 | 405,000.00 |
| Dec 31, 2019 | 407,000.00 |
| Sep 30, 2019 | 399,000.00 |
| Jun 30, 2019 | 437,000.00 |
| Mar 31, 2019 | 442,000.00 |
| Sep 30, 2014 | -1,210.00 |
| Jun 30, 2014 | 1,120.00 |
| Mar 31, 2014 | -2,650.00 |
| Dec 31, 2013 | 3,000.00 |